CXC Chemokine Receptor Type 5 Gene Polymorphisms in a Cohort of Egyptian Patients with Diffuse Large B-Cell Lymphoma

Abstract

<b><i>Background:</i></b> The chemokine receptor CXCR5 is selectively expressed on B cells; it is involved in lymphocyte homing and the development of normal lymphoid tissue. Its principle ligand is CXCL13 or B lymphocyte chemoattractant. Three polymorphisms in the <i>CXCR5</i> gene, rs148351692 C/G, rs6421571 C/T, and rs78440425 G/A, have been identified. <b><i>Objective:</i></b> To assess the genetic polymorphisms of <i>CXCR5</i> and evaluate their possible contribution to the susceptibility and response to therapy of diffuse large B-cell lymphoma (DLBCL). <b><i>Patients and Methods:</i></b> Fifty DLBCL (not otherwise specified) patients and 50 control subjects were included in this study. <i>CXCR5</i> genotypes were determined by PCR-RFLP. <b><i>Results:</i></b> Our study revealed that the <i>CXCR5</i> rs148351692 C/G and rs6421571 C/T gene polymorphisms are associated with an increased risk of developing DLBCL (OR 28.57 [95% CI 8.96–96.56] and 3.45 [1.67–11.83] respectively), while CXCR5 rs78440425 G/A showed no association with the risk of lymphoma. Moreover, the double and triple combined gene polymorphisms are associated with an increased risk of developing DLBCL of approximately 120-fold and 105-fold, respectively. <i>CXCR5</i> gene polymorphisms had no significant impact on disease outcome or response to therapy. <b><i>Conclusions:</i></b> <i>CXCR5</i> gene polymorphisms could be considered a potential risk factor for the development of DLBCL.